Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

A Brazilian research team has eliminated HIV from a patient’s body for 78 consecutive weeks using only medications, without ...

Last year, 444 people in the Netherlands were diagnosed with HIV, the virus that can cause AIDS. Almost 20 years ago, there ...

Eswatini has become the first African country to receive lenacapavir, a twice-yearly HIV prevention injection that global ...

To put this spike into perspective, the rural city of around 32,000 people has now recorded more HIV cases in two years than ...

The drug lenacapavir will be distributed to Eswatini and Zambia — the first step toward providing at least 2 million doses to ...

Infections, including influenza, COVID-19, HIV, hepatitis C and herpes zoster, can raise the risk of cardiovascular disease (CVD), and vaccines could help lower that risk, according to a study ...

About 1,000 doses of Gilead Sciences Inc's drug lenacapavir were delivered to Zambia and Eswatini last Thursday, U.S. and ...

The US has started to provide doses of a Gilead HIV prevention drug to low-income countries, but the program will not include ...

Merck said the combination achieved suppression of the HIV virus at week 48, similar to Biktarvy in the late-stage study.

The Department of Health said the decision reflects its mandate to ensure that all citizens have access to safe, effective, ...